Effect of pegylated interferon on non-responders and relapsers with interferon
Other Title(s)
فاعلية العلاج بعقار الإنترفيرون المحسن لدى مرضى الفيروس الكبدي نوع ج و الغير مستجيبين للإنترفيون التقليدي
Joint Authors
Akbar, Hisham O.
al-Ahwal, Mahmud S.
Source
SQU Journal for Scientific Research : Medical Sciences
Issue
Vol. 4, Issue 1-2 (30 Apr. 2002), pp.9-13, 5 p.
Publisher
Sultan Qaboos University College of Medicine and Health Sciences
Publication Date
2002-04-30
Country of Publication
Oman
No. of Pages
5
Main Subjects
Topics
Abstract AR
الهدف : التحقق من فاعلية الانترفيرون المحسن لدى مرضى مصابين بفيروس الالتهاب الكبدي نوع ج و الغير مستجيبين للانترفيرون التقليدي.
الطريقة : تم علاج 20 مريضا لم يستجيبوا سابقا لعلاج الانترفيرون بدواء الانترفيرون المحسن مع الريبافيرين لمدة سنة واحدة.
النتائج : استجاب 7 مرضى في نهاية العلاج و استمرت استجابة مريضين فقط بعد ستة أشهر من إيقافه و تبين أنهما كانا من المستجيبين مع نهاية العلاج بالانترفيرون سابقا و لكن لم تستمر الاستجابة بعد إيقافه.
الخلاصة : إن علاج الانترفيرون المحسن ربما يكون ناجعا للمرضى الذين لم تستمر استجابتهم مع علاج الانترفيرون التقليدي.
Abstract EN
Objectives :to assess whether a combination of pegylated interferon (interferon conjugated with polyethylene glycol) and ribavirin can improve the response rate in patients with chronic hepatitis C who either did not respond to (Non-responders), or had relapsed after responding to (Relapsers) standard interferon and ribavirin combination therapy.
Patients and methods: In this prospective study, 20 chronic hepatitis C patients (comprising 16 Non-responders and 4 Relapsers to previous treatment with alpha interferon and ribavirin), were treated with pegylated interferon-2b weekly and ribavirin daily for one year.
Eleven patients had genotype 4, eight were of genotype 1 and one patient had genotype 3.
Response to treatment was determined based on normalisation of liver enzymes and negative viral load (assessed using qualitative HCV RNA PCR) at end of treatment (ETR) and 6 months off treatment (SVR). Results : Seven patients (35%) achieved normalisation of liver enzymes and negative viral load at the end of treatment.
However, only 2 patients (10%) managed to retain these levels after six months off treatment.
The latter two patients had been previous Relapsers.
Conclusion : combination of pegylated interferon and ribavirin may be beneficial in previous relapsers with standard interferon-ribavirin combination therapy, but is unlikely to achieve sustained virological response in non-responders.
American Psychological Association (APA)
Akbar, Hisham O.& al-Ahwal, Mahmud S.. 2002. Effect of pegylated interferon on non-responders and relapsers with interferon. SQU Journal for Scientific Research : Medical Sciences،Vol. 4, no. 1-2, pp.9-13.
https://search.emarefa.net/detail/BIM-56641
Modern Language Association (MLA)
Akbar, Hisham O.& al-Ahwal, Mahmud S.. Effect of pegylated interferon on non-responders and relapsers with interferon. SQU Journal for Scientific Research : Medical Sciences Vol. 4, no. 1-2 (Apr. 2002), pp.9-13.
https://search.emarefa.net/detail/BIM-56641
American Medical Association (AMA)
Akbar, Hisham O.& al-Ahwal, Mahmud S.. Effect of pegylated interferon on non-responders and relapsers with interferon. SQU Journal for Scientific Research : Medical Sciences. 2002. Vol. 4, no. 1-2, pp.9-13.
https://search.emarefa.net/detail/BIM-56641
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : pp. 12-13
Record ID
BIM-56641